<DOC>
	<DOCNO>NCT02763800</DOCNO>
	<brief_summary>The objective state study protocol follow : - To investigate safety tolerability three multiple dose regimen BIA 3-202 ( 50 mg twice day , 100 mg twice day 200 mg twice day healthy young male volunteer ) . Part A - To characterise steady state pharmacokinetic pharmacodynamic profile BIA 3-202 healthy young male . Part A - To investigate safety tolerability single multiple dose regimen ( dose determine Part A ) BIA 3-202 , healthy elderly volunteer . Part B - To characterise steady state pharmacokinetic pharmacodynamic profile single multiple dose regimen ( dose determine Part A ) BIA 3- 202 healthy elderly volunteer . Part B</brief_summary>
	<brief_title>Study Investigate Safety , Tolerability , Steady State Pharmacokinetic Pharmacodynamic Profile BIA 3-202</brief_title>
	<detailed_description>This design single centre , phase I , double-blind , randomise , placebocontrolled study three multiple rise dos three sequential group 8 young male healthy volunteer ( Part A ) single group healthy elderly volunteer ( Part B ) . In Part B , 12 healthy elderly volunteer enrol . Ten randomly allocate BIA 3-202 two placebo .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Adult male age 1835 year , body mass index ( BMI ) 1928 kg/m2 . Subjects healthy determine prestudy medical history , physical examination 12lead ECG . Subjects clinical laboratory test acceptable investigator . Subjects negative HbsAg , antiHCV HIV I II test screen . Subjects negative drug abuse alcohol test screen admission . Subjects nonsmoker smoke less 10 cigarette equivalent per day . Subjects able willing give write informed consent . Subjects conform inclusion criterion . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity . Subjects history alcoholism . Subjects history drug abuse . Subjects consume 28 unit alcohol week . Subjects significant infection know inflammatory process screen and/or admission . Subjects acute gastrointestinal symptom time screen and/or admission ( e.g . nausea , vomit , diarrhoea , heartburn ) . Subjects acute infection influenza time screen and/or admission . Subjects use prescription drug within 4 week first dose . Subjects use counter medication , exclude routine vitamin include mega dose vitamin therapy , within one week first dose . Subjects use investigational drug and/or participate clinical trial within 3 month first admission study . Subjects previously receive BIA 3202 . Subjects donate and/or receive blood blood product within 3 month prior screen . Subjects vegetarian , vegan and/or medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Nebicapone</keyword>
</DOC>